Published on 10 Jun 2016
Peter
George, chief executive of clinical trial services firm Clinigen Group
PLC (LON:CLIN) says the company has “made a really big effort to extend
our global footprint” in 2016, and now has a “complete global reach”.
As part of this strategy, the company has teamed up with Swiss group Basilea to start a managed access programme throughout Europe, allowing clinicians’ access to innovative new medicine isavuconazole, used for invasive fungal infections.
Through the programme, the treatment will be available in European countries where it has been approved but is not yet commercially available.
It’s the second programme announced since April, and George says: “We are the market leader in managed access programmes by a long way.”
“We are the global market leader in clinical trial services and drug supply so to really consolidate that position we need to extend our global footprint,” he adds
.
www.clinigengroup.com/
http://www.4-traders.com/CLINIGEN-GROUP-PLC-11560493/
www.proactiveinvestors.com/LON:CLIN/Clinigen-Group-PLC/
#IdisMA and Basilea initiate EU Managed Access program for patients with invasive fungal infections https://t.co/WKJQEXB85v #isavuconazole
— Clinigen Group (@Clinigen) June 9, 2016
Apr 24 - Apr 27 #UK#CLINIGEN has published new team member: David Moranhttps://t.co/qx7iD5LmOT#PHARMACEUTICALANDSERVICES
— LSE Monitor (@LSEMonitor) April 28, 2016
#Clinigen : joins two key European alliances in the fight to protect patients ... https://t.co/GLkyd5WKEF $CLIN
— 4-traders.com (@ForTraders) March 30, 2016
